Mitchell Smith
Professor of Medicine, Director of Cancer and Blood Disorders Division
GW Cancer Center, George Washington University · Washington, United States
Former Director of Lymphoid Malignancy Program at Cleveland Clinic and Fox Chase Cancer Center. Extensive clinical trial experience in lymphoma.
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.
Blood · Jul 22, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
American journal of hematology · Jun 17, 2026
Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.
American journal of hematology · May 4, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.
Blood advances · Mar 19, 2026
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.
Hematology. American Society of Hematology. Education Program · Dec 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
Nature communications · Nov 5, 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Oct 31, 2025
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · Oct 1, 2025
Translocations can drive expression changes of multiple genes in regulons covering entire chromosome arms.
Nucleic acids research · Aug 11, 2025
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.
Haematologica · Mar 1, 2025
Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
Cancer chemotherapy and pharmacology · Feb 28, 2025
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Blood advances · Sep 10, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 5, 2024
Antibrush Border Antibody Disease: A Case Series.
Kidney medicine · Jul 1, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Blood advances · Jun 25, 2024
Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells.
Clinical cancer research : an official journal of the American Association for Cancer Research · May 1, 2024
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Blood advances · Mar 26, 2024
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Blood advances · Mar 12, 2024
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica · Jan 1, 2024